E, P.M., P, C.A., C, M.W., L, M.S., G, S.M., Jeffrey, K., & D, D.A. (2026). Microaxial Flow Pumps in Heart Failure Related Cardiogenic Shock - From Hemodynamic Mechanisms to Clinical Applications: A State-of-the-Art-Review.. Journal of cardiac failure.
E PM, P CA, C MW, L MS, G SM, Jeffrey K, et al. Microaxial Flow Pumps in Heart Failure Related Cardiogenic Shock - From Hemodynamic Mechanisms to Clinical Applications: A State-of-the-Art-Review.. Journal of cardiac failure. 2026; PMID: 42097529
E PM, P CA, C MW, et al. Microaxial Flow Pumps in Heart Failure Related Cardiogenic Shock - From Hemodynamic Mechanisms to Clinical Applications: A State-of-the-Art-Review.[J]. Journal of cardiac failure. 2026.
@article{e2026,
author = {Prescott Meagan E and Carnicelli Anthony P and Mostertz William C and McCartney Sharon L and Sanders Mason G and Keenan Jeffrey and DeVore Adam D},
title = {Microaxial Flow Pumps in Heart Failure Related Cardiogenic Shock - From Hemodynamic Mechanisms to Clinical Applications: A State-of-the-Art-Review.},
journal = {Journal of cardiac failure},
year = {2026},
note = {PMID: 42097529},
}
TY - JOUR AU - Prescott Meagan E AU - Carnicelli Anthony P AU - Mostertz William C AU - McCartney Sharon L AU - Sanders Mason G AU - Keenan Jeffrey AU - DeVore Adam D TI - Microaxial Flow Pumps in Heart Failure Related Cardiogenic Shock - From Hemodynamic Mechanisms to Clinical Applications: A State-of-the-Art-Review. T2 - Journal of cardiac failure PY - 2026 AN - PMID:42097529 ER -
Heart failure-related cardiogenic shock (HF-CS) is now the leading etiology of cardiogenic shock (CS). Advances in temporary mechanical circulatory support (tMCS), particularly microaxial flow pumps (mAFP), alongside evolving organ procurement and heart-allocation policies, have expanded opportunities for hemodynamic stabilization, recovery, and heart replacement therapy. However, prolonged support capabilities have increased the complexity of clinical decision-making in a heterogeneous population with variable candidacy for heart replacement therapies if native heart recovery (NHR) is not achieved. Optimal use of mAFP requires integration of device-specific capabilities with patient-level hemodynamics and overall clinical context.